Nemolizumab

From Wikipedia, the free encyclopedia
Nemolizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL31RA
Clinical data
Other namesCIM-331
Routes of
administration
Subcutaneous injection
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
MetabolismProteolytic enzymes
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.[2] Results of a Phase II clinical trial were published in March 2017.[3]

Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[4]

References[edit]

  1. ^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 74" (PDF). WHO Drug Information. World Health Organization. 29 (3): 411. 2015.
  3. ^ Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. (March 2017). "Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis". The New England Journal of Medicine. 376 (9): 826–835. doi:10.1056/NEJMoa1606490. PMID 28249150. S2CID 205100502.
  4. ^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.